AQB AquaBounty Technologies, Inc.
Company Updates ·
On October 23, 2026, after its resale registration became effective, all Series A and Series B preferred shares converted into common stock, leaving 13,291,953 common shares outstanding.
AquaBounty agreed on October 7, 2026 that all Series A and Series B preferred stock will convert into 8,077,043 common shares by October 30, 2026 at the latest, with the resale shares to be registered.
AquaBounty said on August 6, 2026 that its review of the Pioneer, Ohio property now covers power infrastructure and energy development, alongside its aquaculture sale talks.
AquaBounty's board decided on July 6, 2026 not to carry out a reverse split of 1-for-5 to 1-for-20 that stockholders approved, and that authority expires July 31, 2026.
The private placement closed June 25, 2026, with Univest Securities, LLC as placement agent. The shares carry an 18.0% annual dividend and a $1.03 conversion price.
A note exchange and a $500,000 preferred sale both closed April 7, 2026. Univest Securities, LLC was the placement agent for the offering.
AquaBounty told the SEC on September 17, 2025 that Nasdaq closed its $1.00 bid price matter after a January 15, 2025 notice. The company no longer runs any salmon farm, and its 10-K puts 2024 impairments at $129.8 million.
AquaBounty Technologies, Inc. previously pursued land-based salmon farming using its genetically engineered Atlantic salmon. The company says it does not currently operate any salmon farms, having sold its Indiana grow-out farm in July 2024 and its Canadian subsidiary, including the Prince Edward Island broodstock farms, along with the intellectual property for its GE Atlantic salmon, in March 2025. Its primary remaining asset is the Ohio Farm Project in Pioneer, Ohio, a planned 10,000 metric ton recirculating aquaculture farm. Construction was paused in June 2023 after cost estimates rose. The Ohio project is now classified as a discontinued operation and as held for sale. The company received a non-binding Letter of Interest to purchase its Ohio subsidiary, which it is considering, and it continues to sell selected Ohio equipment to generate liquidity while working with an investment bank on the path forward. The company recorded impairment charges of $14.4 million in 2025 and $129.8 million in 2024. The text cites a Food and Agriculture Organization estimate that aquaculture was a $296 billion industry in 2022, with salmon farming accounting for $22 billion.
| Product or program | What it is | Stage |
|---|---|---|
| Ohio Farm Project | Planned 10,000 metric ton recirculating aquaculture farm in Pioneer, Ohio | Construction paused June 2023; held for sale |
| GE Atlantic salmon | Genetically engineered Atlantic salmon, formerly farmed by the company | Intellectual property sold March 2025; no salmon farms operated |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $203,296 | |
| Net income (loss) | -$18.5 million | -$149.2 million |
| Cash from operations | -$8.7 million | -$13.9 million |
| Cash and equivalents | $501,295 | $230,362 |
Our latest story on this, dated Jul 8, 2026: "AquaBounty's board declines reverse stock split for now". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 25, 2026: "AquaBounty sells $2,250,000 of Series B preferred stock". The story links the filing or release it is based on. Read the story.
AquaBounty Technologies, Inc. trades under the ticker AQB on NASDAQ.
AquaBounty Technologies, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for AquaBounty Technologies, Inc. is 1603978. Its filings are on SEC EDGAR.
5,147,204 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records AquaBounty Technologies, Inc. under United States.
Our directory classifies AquaBounty Technologies, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for AquaBounty Technologies, Inc. is US03842K3095.
aibio.space lists AquaBounty Technologies, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
AquaBounty Technologies, Inc. previously pursued land-based salmon farming using its genetically engineered Atlantic salmon. The company says it does not currently operate any salmon farms, having sold its Indiana grow-out farm in July 2024 and its Canadian subsidiary, including the Prince Edward Island broodstock farms, along with the intellectual property for its GE Atlantic salmon, in March 2025.
Ohio Farm Project: Planned 10,000 metric ton recirculating aquaculture farm in Pioneer, Ohio Stage: Construction paused June 2023; held for sale.
GE Atlantic salmon: Genetically engineered Atlantic salmon, formerly farmed by the company Stage: Intellectual property sold March 2025; no salmon farms operated.
AquaBounty Technologies, Inc. reported a net loss of $18.5 million for the fiscal year ended Dec 31, 2025, and used $8.7 million of cash in operations, per its annual report to the SEC.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio